The Novo Nordisk head-and-shoulders pattern is taking shape, with a target price of $97. While the long-term outlook remains bullish, the hype around weight loss drugs is cooling off due to increasing competition and growing awareness of potential unknown side effects.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.